An innovative approach to the assessment of mood disturbances in patients with acute coronary syndrome

Sara Gostoli1, Sara Buzzichelli2, Jenny Guidi1, Laura Sirri1, Enrica Marzola2, Renzo Roncuzzi3, Giovanni Abbate-Daga1, Giovanni A. Fava4 and Chiara Rafanelli1*

1Department of Psychology, University of Bologna, Bologna, Italy, 2Eating Disorders Center for Treatment and Research, Department of Psychology, University of Turin, Turin, Italy, 3Division of Cardiology, Bellaria Hospital, AUSL Bologna, Bologna, Italy, and 4Department of Psychiatry, University at Buffalo, Buffalo, New York, USA

Abstract

Background. The clinical value of the identification of mood disorders in patients with acute coronary syndrome (ACS) is well established. However, assessment based on DSM criteria presents some limitations. This study aimed to provide an innovative strategy for evaluating the spectrum of mood disturbances in ACS.

Methods. A total of 288 patients with a first episode of ACS underwent interviews based on DSM-IV-TR criteria (major depressive disorder, minor depression, and dysthymia), Diagnostic Criteria for Psychosomatic Research–DCPR (demoralization and type A behavior), and the Clinical Interview for Depression–CID. Additional self-report inventories (psychological well-being and distress) were administered. A total of 100 consecutive patients who satisfied criteria for DSM-IV-TR depression or DCPR demoralization were enrolled in a randomized controlled trial on a sequential combination of cognitive-behavioral and well-being therapy (CBT/WBT) vs clinical management (CM) and reassessed up to 30-month post-intervention.

Results. A total of 29.9% of patients showed a DSM-IV-TR depressive syndrome. Inclusion of demoralization and type A identified psychological distress in 58% of the sample. According to CID, reactivity to social environment, fatigue, depressed mood, and somatic anxiety were the most common symptoms. Somatic symptoms were significantly associated with DSM-IV-TR depression (fatigue and changes of appetite), whereas environmental reactivity with demoralization. Both depression and demoralization were associated with higher distress and lower well-being. Unlike CM, CBT/WBT was significantly associated with decrease of guilt, pessimism, fatigue, and early insomnia (CID).

Conclusions. The findings indicate that standard psychiatric approach identifies only a narrow part of mood disturbances affecting ACS patients. A more articulated assessment unravels specific clinical configurations that may entail prognostic and therapeutic implications.

Introduction

There is a large body of literature documenting the high prevalence of mood disorders in acute coronary syndromes (ACS)1 and their associations with poor therapeutic adherence, higher frequency of relapses, and increased mortality.2,3 Mood disturbances may consist of major or minor depressive episodes, chronic depression, and demoralization.2,4,5 The latter is characterized by a sense of subjective incompetence6 and it may co-occur with depression or be independent, as demoralization was found to be distinguishable from minor depression7-10 and dysthymia.9,10 Key depressive symptoms, such as disturbances in mood, fatigue, and early insomnia (CID). The hypothesis that certain clusters of symptoms could be more relevant for cardiac prognosis than others, in terms of “cardio-toxicity”11 has been supported by the recent position paper of the European Society of Cardiology,1 which recognizes that specific subtypes of depression (treatment-resistant, post-ACS, and somatic symptoms-related depression) might be more strongly associated with ACS risk than others, thus confirming that a qualitative evaluation of depression (and its subsequent treatment) would improve prognosis.

According to this clinical perspective, it is necessary to develop a broad and sensitive assessment of depression in cardiac units. It has been underlined that traditional psychiatric nosography alone, such as that reported in the Diagnostic and Statistical Manual of Mental Disorders (DSM), might not be able to provide sufficient clinical information.12 The customary clinical taxonomy in psychiatry, in fact, does not take into consideration specific clinical features

Key words:
Acute coronary syndrome, clinimetric criteria, demoralization, depression, psychological well-being, type A behavior

Author for correspondence:
*Chiara Rafanelli, MD, PhD
Email: chiara.rafanelli@unibo.it

© The Author(s), 2021. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
that may demarcate major prognostic and therapeutic differences among patients who otherwise would be misleadingly classified into the same diagnostic category or whose affective symptoms would eventually gone unrecognized. It has been suggested that the assessment might take advantage from a clinimetric approach that reflects the clinical process underling decisions in practice, providing a framework for the reproduction and standardization of clinical intuitions.

The purpose of this study was to broaden the evaluation of depressive symptomatology in ACS patients by using a clinimetric approach in order to identify clinical phenomena such as symptom severity, timing of phenomena, and comorbid conditions relevant to cardiac disease. More specifically, the current investigation was aimed at identifying not only traditional psychiatric nosography (ie, major/minor depression and dysthymia), but also severity and longitudinal course of depressive symptomatology, as well as other qualitatively different psychological conditions, such as demoralization, type A behavior and psychological well-being.

Methods

Sample

Seven hundred and forty consecutive patients who suffered from a first episode of ACS (ie, acute myocardial infarction or unstable angina) were screened by the cardiologists at the Divisions of Cardiology of two hospitals in Northern Italy (Molinette Hospital in Turin and Maggiore Hospital in Bologna). Acute myocardial infarction was documented by cardiac symptoms (ie, presence of acute chest-, epigastric-, neck-, jaw-, or arm- pain, discomfort or pressure without apparent noncardiac source) and signs (ie, acute congestive heart failure or cardiogenic shock in the absence of non-CHD causes), associated with ECG findings (characteristic evolutionary ST-T changes or new Q waves) and/or cardiac biomarkers (blood measures of myocardial necrosis, specifically CK, CK-MB, CK-MBm, or troponin, cTn). Instable angina was acknowledged by cardiac symptoms (chest pain lasting less than 20 minutes) with likely ECG findings (ST-segment depression and abnormal T-wave) in absence of myocardial necrosis biomarkers. Among the initial 740 patients, 288 agreed to undergo the psychological assessment and thus were enrolled in the present study.

Study design

The whole sample (N = 288) was assessed at baseline for screening purposes related to a randomized controlled trial, the TREATED-ACS Study. The first 100 consecutive depressed (according to DSM-IV-TR)14 and/or demoralized (according to Diagnostic Criteria for Psychosomatic Research—DCPR)15 patients entered the trial and were reassessed at the end of the interventions sessions, and after 3, 6, 12, and 30 months. In this latter group, patients were randomly assigned to either a sequential combination of cognitive-behavioral therapy (CBT) and well-being therapy (WBT)16 or to clinical management (CM), an active form of control in which specific psychological strategies were proscribed, albeit CM patients received the same amount of time and attention as CBT/WBT patients. The full study protocol and outcomes are detailed in a previous work.13 The sequential combination of CBT and WBT was associated with a greater significant improvement in depressive symptoms (from pre- to post-treatment) than that reported in CM, as indicated by a larger effect size. However, the superiority of CBT/WBT group faded starting from 3-month follow-up. In both groups, the improvement of depressive symptomatology persisted up to 30-month follow-up. Treatment was also related to a significant amelioration of biomarkers (platelet count, HDL, and D-dimer), whereas both groups showed similar frequencies of adverse cardiac events.13

The study was approved by the institutional review board of the ethics committees of Bologna (identifier: “Studio CE 09058,” AUSL Bologna) and Turin (identifier: “CPW28Y_002,” Comitato Etico Interaziendale A.O.U. San Giovanni Battista and A.O. “C.T.O. Maria Adelaide” Turin) and registered on ClinicalTrials.gov (identifier: NCT00998400). Written informed consent was secured from all of the patients for both the initial psychological evaluation and trial participation, after the procedures had been fully explained to them. The participants did not receive any compensation. All the procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Assessment

Baseline psychological evaluation was performed 1 month after the hospitalization for the ACS episode, in order to minimize the chance to detect transient ACS-related depressive symptomatology. Participants underwent detailed semistructured clinical interviews and observer-rated scales by a trained clinical psychologist and completed self-rating questionnaires for the assessment of subclinical psychological distress and well-being, as follows.

(a) The Structured Clinical Interview for DSM-IV-TR (SCID-I)18 was used to identify depressive disorders. In order to qualify for a diagnosis of major depression, patients had to exhibit at least five (at least two for minor depression) out of nine symptoms, including either depressed mood or loss of interest and/or pleasure. Minor depression was classified as “other specified depressive disorder, depressive episode with insufficient symptoms” (ie, characterized by insufficient number of symptoms to meet the criteria for major depressive disorder) in DSM-5.17 As to dysthymia, which was relabeled to “persistent depressive disorder” in DSM-5,17 patients had to report at least two additional depressive symptoms in addition to depressed mood for most of the day, for more days than not, and for at least 2 years.14

(b) The Semistructured Interview based on the Diagnostic Criteria for Psychosomatic Research (SSI-DCPR)15,20 was used to detect demoralization and Type A behavior. Diagnoses were formulated independently of DSM-IV-TR diagnostic findings. Items of the SSI-DCPR are scored through a dichotomous format (ie, yes or no) response format and the interview contains skip instructions. The interview based on DCPR demonstrated high inter-rater reliability, with Cohen’s kappa for demoralization and Type A equal to 0.90 and 0.92, respectively.21,22

(c) The 20-item change version of Clinical Interview for Depression (CIDI)23,24 was selected to assess quality and severity of depressive symptoms. This dimensional observer-rated instrument represents an expanded version of the Hamilton Rating Scale for Depression.25,26 The interview covers 20 symptom areas and each item is rated on a 7-point Likert scale, with a score of 1 indicating the absence of symptoms and 7 severe debilitating manifestations, with specification of each anchor point based on the severity, frequency, and/or quality of symptoms. The higher the score, the worse the psychological
condition. A score of 3 or above in each item was considered as the cut-off for the presence of the symptom, at least at a subclinical level. The scale encompasses a wide range of symptoms (such as irritability and phobic anxiety) compared to other scales and it is particularly suitable to assess subclinical symptoms of mood disorders. One additional item concerning reactivity to social environment, selected from the full version of the CID, was included.

(d) The Symptom Questionnaire (SQ) constitutes a self-reported measure on subclinical psychological distress. It includes 92 items that yield 4 main scales, that is, depression, anxiety, hostility-irritability, and somatization. Each item has to be answered on a dichotomous format (ie, yes/true or no/false) and the higher the score, the higher the psychological distress.

(e) The psychological well-being (PWB) scales is a self-report 84-item questionnaire, for evaluating six inter-related areas of PWB and optimal functioning (ie, autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance). Items have to be rated on a 6-point Likert scale and higher scores correspond to greater PWB in each dimension.

Statistical analyses

Data were analyzed using SPSS 20.0 (SPSS Inc., Chicago, IL). Descriptive analyses were run for frequencies of specific depressive symptoms, as assessed by CID, and frequencies of DSM-IV-TR depressive disorders (ie, major/minor depression and dysthymia), DCPR demoralization, and type A behavior in the total sample. Chi-square test, applied to contingency tables, was used to compare the prevalence of DSM-IV-TR depressive disorders and DCPR demoralization with the frequencies of CID depressive symptoms. Multivariate analyses of variance using the general linear model were performed to test for associations between DSM-IV-TR depressive disorders, DCPR demoralization and average scores on dimensional psychological measures (SQ and PWB). Diagnoses formulated according to DSM-IV-TR and DCPR were examined separately.

By means of the GenLin command (indicating binomial as the probability distribution and logit as the link function to be used in the model), mixed-design repeated measures logistic regression was performed. This procedure allowed the evaluation of Time × Group allocation effect on multiple evaluations of CID depressive symptoms (ie, binary outcomes), including all the follow-up evaluations of each patient allocated to either the sequential combination of CBT and WBT or CM.

For all tests performed, the significance level was set at 0.05, two-tailed. In view of the exploratory nature of the investigation, adjustment for multiple testing was not performed.

Results

ACS patients’ characteristics

Patients’ response rate was 38.9% (N = 288 out of 740 ACS patients). Four hundred and fifty-two patients (35.4% females) refused to undergo the psychological assessment, mainly because of severe medical condition (35%), lack of interest (31%), or logistical problems (23%).

Descriptive sociodemographic characteristics of the study population are presented in Table 1. The sample included mainly men (81.3%) with a mean age of 61.53 years (SD = 10.85), ranging from 33 to 86 years. Most of the participants were employed (47.2%), married (72.6%) and had a high school diploma (35.4%).

Table 1. Sociodemographic Characteristics of the Patients with Acute Coronary Syndrome (ACS) (N = 288)

| Variable                  | Mean | SD |
|---------------------------|------|----|
| Age                       | 61.53| 10.85 |
| Sex (male)                | 234  | %  |
| Occupation                |      |    |
| Employed                  | 136  | 47.2 |
| Retired                   | 125  | 43.4 |
| Homemaker                 | 14   | 4.9 |
| Unemployed                | 13   | 4.5 |
| Marital status            |      |    |
| Married                   | 209  | 72.6 |
| Single                    | 30   | 10.4 |
| Separated/Divorced        | 28   | 9.7 |
| Widow/Widower             | 21   | 7.3 |
| Education                 |      |    |
| Primary school            | 51   | 17.7 |
| Middle school             | 98   | 34  |
| High school               | 102  | 35.4 |
| University                | 26   | 9   |
| Postgraduate education    | 11   | 3.8 |

Relationship of DSM-IV-TR depressive disorders, DCPR demoralization, and type A behavior

Figure 1 describes the diagnostic profile of the sample (N = 288). One hundred and ten patients (38.2%) neither received a diagnosis of mood disturbance (ie, DSM-IV-TR depressive disorders or DCPR demoralization), nor satisfied criteria for type A behavior. Demoralization was the most frequently reported diagnosis (N = 123, 42.7% of the whole sample). Thirty-six (29.3% of demoralized patients) presented with demoralization alone, whereas 14 had comorbid type A behavior. The remaining 73 demoralized participants reported a comorbidity with mood disturbances according to DSM-IV-TR. As to DSM-IV-TR depressive disorders, minor depression was the most frequently reported mood disorder (N = 74, 25.7% of the whole sample). Ten (13.5% of patients with minor depression) presented with this diagnosis alone, whereas major depression (N = 8, 2.8% of the whole sample) and dysthymia (N = 4, 1.4% of the whole sample) were always diagnosed in comorbidity with demoralization, except one case of dysthymia. Eighty-one patients (28.1% of the whole sample) reported type A behavior and, among them, more than a half (N = 42, 14.6% of the whole sample) did not show any comorbid mood disturbance.

If the assessment had relied uniquely on DSM-IV-TR, 70.1% of the patients would have been labeled as “unaffected,” with only 29.9% (N = 86) of the sample receiving a diagnosis of mood disturbance.
disorder, mainly minor depression. Instead, the joint use of the DCPR system allowed the identification of psychological distress in 58% (N = 167) of the sample.

As to past diagnoses, 41% of the sample (N = 118) reported to have a positive history of DSM-IV-TR depression, whereas 42% (N = 121) of DCPR demoralization.

**Frequency of depressive symptoms in ACS patients**

The frequencies of all CID items are presented in Table 2. The most common CID depressive symptoms in patients who suffered from a first episode of ACS were high environmental reactivity (59.4%, N = 171) and low energy and fatigue (50.7%, N = 146), followed by depressed mood (36.1%, N = 104) and somatic anxiety (35.4%, N = 102).

Overall, DSM-IV-TR depressive disorders and DCPR demoralization were associated with a greater severity of symptoms, except for delayed insomnia, agitation, hostility, and panic attacks (Table 2). Significant associations of CID symptoms with DSM-IV-TR depressive disorders or with DCPR demoralization were found as well. In particular, low energy and fatigue (P < .001), as well as changes of appetite (anorexia: P < .001; increased appetite: P < .01), were uniquely associated with DSM-IV-TR depressive disorders. Environmental reactivity (P < .001) was exclusively associated with DCPR demoralization.

---

**Figure 1.** Prevalence of DSM-IV-TR depressive disorders (major depressive disorder, minor depression, and dysthymia), DCPR demoralization and Type A behavior in ACS patients. ACS, acute coronary syndrome; DCPR, diagnostic criteria for psychosomatic research.
Associations between DSM-IV-TR depressive disorders and dimensional psychological variables

According to multivariate analyses of variance comparisons (Table 3), the presence of DSM-IV-TR depression (ie, major, minor depression, or dysthymia) was significantly associated with higher scores of psychological distress in all SQ scales (all P values < .001) and lower scores of PWB in all PWB dimensions (from P = .004 to P < .001), except for autonomy.

Associations between DCPR demoralization and dimensional psychological variables

Concerning DCPR demoralization, multivariate analyses of variance indicated that the presence of this syndrome was significantly associated with higher scores in all SQ scales (all P values < .001), as well as with lower scores in all PWB dimensions (from P = .020 to P < .001) (Table 3).

Effects of CBT/WBT compared to CM on depression-related symptoms

Considering the first 100 depressed/demoralized consecutive patients who joined the TREATED-ACS Study and received the interventions, GenLin procedure showed that the interaction Time × Group allocation (either CBT/WBT or CM) was significant for guilt (Wald Chi-square = 12.05, df = 5, P < .05), pessimism (Wald Chi-square = 12.76, df = 5, P < .05), low energy/fatigue (Wald Chi-square = 14.45, df = 5, P < .05), somatic anxiety (Wald

Abbreviations: ACS, acute coronary syndrome; CID, clinical interview for depression; DCPR, diagnostic criteria for psychosomatic research; DSM, diagnostic and statistical manual of mental disorders.

Table 2. Frequency of Depression-Related Symptoms (CID Items) in ACS Patients (N = 288) and their Associations with DSM-IV-TR Depressive Disorders (ie, Major Depression, Minor Depression, and Dysthymia) and DCPR Demoralization

| CID Item                  | Total Sample N = 288 | DSM Depression (+) N = 86 | DSM Depression (−) N = 202 | χ²  | P     | DSM Depression (+) N = 132 | DSM Depression (−) N = 165 | χ²  | P     |
|--------------------------|----------------------|---------------------------|---------------------------|-----|-------|---------------------------|---------------------------|-----|-------|
| Environmental reactivity | 171 (59.4)           | 57 (66.3)                 | 114 (56.4)                | 2.80| .094  | 89 (72.4)                 | 82 (49.7)                 | 15.75| <.001 |
| Energy and fatigue       | 146 (50.7)           | 61 (70.9)                 | 85 (42.1)                 | 21.09| <.001 | 70 (56.9)                 | 76 (46.1)                 | 3.59 | .058  |
| Depressed mood           | 104 (36.1)           | 76 (88.4)                 | 28 (13.9)                 | 147.79| <.001 | 88 (71.5)                 | 16 (9.7)                  | 118.33| <.001 |
| Somatic anxiety          | 102 (35.4)           | 47 (54.7)                 | 55 (27.2)                 | 20.57| <.001 | 52 (42.3)                 | 50 (30.3)                 | 4.65 | .031  |
| Generalized anxiety      | 89 (30.9)            | 44 (51.2)                 | 45 (22.3)                 | 24.32| <.001 | 58 (47.2)                 | 31 (18.8)                 | 27.10| <.001 |
| Pessimism                | 85 (29.5)            | 53 (61.6)                 | 32 (15.8)                 | 62.09| <.001 | 69 (56.1)                 | 16 (9.7)                  | 73.89| <.001 |
| Irritability             | 85 (29.5)            | 43 (50)                   | 42 (20.8)                 | 25.48| <.001 | 53 (43.1)                 | 32 (19.4)                 | 19.46| <.001 |
| Phobic anxiety           | 80 (27.8)            | 40 (46.5)                 | 40 (19.8)                 | 22.11| <.001 | 43 (35.0)                 | 37 (22.4)                 | 5.74 | .017  |
| Guilt                    | 78 (27.1)            | 54 (62.8)                 | 24 (11.9)                 | 80.64| <.001 | 66 (53.7)                 | 12 (7.3)                  | 77.71| <.001 |
| Work and interests       | 68 (23.6)            | 43 (50)                   | 25 (12.4)                 | 48.32| <.001 | 50 (40.7)                 | 18 (10.9)                 | 35.09| <.001 |
| Delayed insomnia         | 48 (16.7)            | 18 (20.9)                 | 30 (14.9)                 | 1.72 | .190  | 17 (13.8)                 | 31 (18.8)                 | 1.19 | .276  |
| Depressed appearance     | 45 (15.6)            | 37 (43.0)                 | 8 (4.0)                   | 70.85| <.001 | 35 (28.5)                 | 10 (6.1)                  | 27.16| <.001 |
| Phobic avoidance         | 45 (15.6)            | 25 (29.1)                 | 20 (9.9)                  | 17.23| <.001 | 27 (22.0)                 | 18 (10.9)                 | 6.68 | .010  |
| Early insomnia           | 36 (12.5)            | 16 (18.6)                 | 20 (9.9)                  | 4.34 | .037  | 21 (17.1)                 | 15 (9.1)                  | 4.22 | .040  |
| Anorexia                 | 27 (9.4)             | 16 (18.6)                 | 11 (5.4)                  | 12.56| <.001 | 16 (13.0)                 | 11 (6.7)                  | 3.42 | .064  |
| Increased appetite       | 24 (8.3)             | 13 (15.1)                 | 11 (5.4)                  | 7.57 | .006  | 14 (11.4)                 | 10 (6.1)                  | 2.68 | .101  |
| Agitation                | 24 (8.3)             | 10 (11.6)                 | 14 (6.9)                  | 1.82 | .177  | 12 (9.8)                  | 12 (7.3)                  | 0.60 | .438  |
| Suicidal tendencies      | 12 (4.2)             | 11 (12.8)                 | 1 (0.5)                   | 23.13| <.001 | 11 (8.9)                  | 1 (0.6)                   | 12.38| <.001 |
| Psychomotor retardation  | 9 (3.1)              | 9 (10.5)                  | 0 (0)                     | 22.08| <.001 | 8 (6.5)                   | 1 (0.6)                   | 8.18 | .004  |
| Hostility                | 8 (2.8)              | 1 (1.2)                   | 7 (3.5)                   | 1.16 | .282  | 2 (1.6)                   | 6 (3.6)                   | 1.03 | .310  |
| Panic attacks            | 2 (0.7)              | 1 (1.2)                   | 1 (0.5)                   | 0.40 | .526  | 2 (1.6)                   | 0 (0)                     | 2.72 | .099  |

Abbreviations: ACS, acute coronary syndrome; CID, clinical interview for depression; DCPR, diagnostic criteria for psychosomatic research; DSM, diagnostic and statistical manual of mental disorders.
Table 3. Association of DSM-IV-TR Depressive Disorders (ie, Major Depression, Minor Depression, and Dysthymia) and DCPR Demoralization with Dimensional Psychological Measures (N = 288)

| Variable                  | Mean (SD) | Mean (SD) | FP Partial Eta ^2 | Partial Eta ^2 | SQ anxiety | 8.86 (4.74) | 4.38 (3.96) | 66.720 ^a < .001 | 0.194 | 8.44 (4.67) | 3.65 (3.47) | 96.368 ^a < .001 | 0.258 |
|----------------------------|-----------|-----------|-------------------|----------------|-------------|-------------|-------------|-------------------|--------|-------------|-------------|-------------------|--------|
| SQ depression              | 8.61 (4.19) | 4.34 (3.18) | 201.563 ^< .001 | 0.503 | 9.00 (5.57) | 5.98 (4.34) | 65.54 (9.12) | 0.140 |
| SQ hostility               | 3.12 (2.35) | 38.674 ^< .001 | 0.123 | 5.75 (5.61) | 2.74 (2.87) | 65.54 (9.12) | 0.140 |
| PWB autonomy               | 62.68 (9.59) | 62.29 (8.91) | 5.18 ^< .001 | 0.034 | 65.12 ^< .001 | 0.034 |
| PWB personal growth        | 55.45 (10.28) | 60.28 (3.28) | 5.48 ^< .001 | 0.136 | 64.85 (9.12) | 0.177 |
| PWB purpose relations      | 55.17 (11.90) | 55.26 (10.62) | 3.74 ^< .001 | 0.052 | 64.85 (9.12) | 0.177 |
| PWB self-acceptance        | 54.28 (12.23) | 67.17 (9.83) | 0.5450 ^< .001 | 0.174 | 64.85 (9.12) | 0.177 |

Note: (þ) Disorder or syndrome absent. Abbreviations: DCPR, diagnostic criteria for psychosomatic research; DSM, diagnostic and statistical manual of mental disorders; PWB, psychological well-being scales; SQ, symptom questionnaire.

Chi-square = 11.61, df = 5, P < .05, and early insomnia (Wald Chi-square = 12.68, df = 5, P < .05) (Table 4).

Specifically, the sequential intervention (CBT/WBT) was significantly related to decreased feelings of guilt (Wald Chi-square = 4.58, df = 1, P < .05; Exp(B) = 2.80, 95%CI: 1.09-7.21) and pessimism (Wald Chi-square = 9.96, df = 1, P < .01; Exp(B) = 5.56, 95%CI: 1.92-16.11), from baseline to post-treatment (both P < .001), with benefits maintained up to 30-month follow-up. Moreover, CBT/WBT was significantly associated with a reduction of somatic depressive symptoms, such as low energy/fatigue (Wald Chi-square = 9.07, df = 1, P < .01; Exp(B) = 4.19, 95%CI: 1.65-10.64) and early insomnia (Wald Chi-square = 8.50, df = 1, P < .01; Exp(B) = 13.17, 95%CI: 2.33-74.57), from baseline to post-treatment (both P < .001 and P = .011, respectively), with benefits maintained up to 12-month follow-up in the first case, and fluctuating over time in the case of insomnia (from 3- to 12-month follow-up: P > .05; 30-month follow-up: P = .016). The only exception was somatic anxiety, in which a significant reduction of symptoms was observed in CM group only between baseline and post-intervention (P = .031) with benefits maintained at subsequent follow-ups, except at 3-month follow-up.

Finally, as to depressed mood, no significant Time × Group interaction was found. Indeed, in both CBT/WBT and CM groups a significant decrease of depressed mood from baseline to post-treatment was found (P < .001 and P = .002, respectively), and maintained up to 30-month follow-up.

Discussion

Determination of depressive disorders according to DSM diagnostic criteria 14 is essentially based on the number of key depressive symptoms that are present, for example, at least five of a set of nine symptoms should be present (and one should be either depressed mood or loss of interest). However, setting a clinical threshold merely on the basis of these criteria may be problematic in ACS, particularly in the acute phase of illness,17 and may miss important clinical information. In this investigation, an innovative approach to the assessment of mood disturbances was attempted. Hospitalization carries a considerable amount of distress that tends to subside with discharge11; patients underwent psychological evaluation 1 month after the acute event. Further, the characteristics, quality and severity of each depressive symptom were assessed using a highly sensitive and accurate observer-rated scale, the CID.23,24 Two additional related syndromes, demoralization and type A behavior,7,15,20 were identified. Finally, self-report measures of subclinical distress, the SQ,27,28 and the PWB,29,30 were included.

Based on DSM criteria only, less than one third of ACS patients (29.9%) received a diagnosis of mood disorder, mainly minor depression, whereas the DCPR system substantially increased the likelihood of identifying mood disturbances (58% of cases). Further, the most commonly reported symptoms, according to CID, were abnormal reactivity to social environment, low energy/fatigue, depressed mood, and somatic anxiety, with specific depressive somatic symptoms uniquely associated with DSM depression, whereas environmental reactivity with demoralization. Both depressed and demoralized patients reported significantly higher distress and lower well-being than their counterparts, except for autonomy scores, that were similar in depressed and nondepressed patients. The sequential combination of CBT and WBT was associated with a significant decrease in symptoms such as guilt, pessimism, fatigue, and early insomnia, as assessed by CID.
| CID Item                  | Parameter                  | B    | SE    | Wald Chi-square | P    | Exp (B) | Wald 95% CI for Exp(B) | Test of the Model Effect Time × Group | Wald Chi-square | P  |
|--------------------------|----------------------------|------|-------|-----------------|------|---------|------------------------|--------------------------------------|----------------|-----|
|                           |                            |      |       |                 |      |         | Lower                  | Upper                                |                |     |
|                           |                            |      |       |                 |      |         |                         |                                      |                |     |
| Depressed mood           | 30-Mo Follow-up × Group    | 0.385| 0.610 | 0.399<sup>a</sup> | .528 | 1.470   | 0.445                  | 4.855                                |                |     |
|                           | 12-Mo Follow-up × Group    | 1.068| 0.581 | 3.379<sup>a</sup> | .066 | 2.909   | 0.932                  | 9.085                                |                |     |
|                           | 6-Mo Follow-up × Group     | 0.826| 0.574 | 2.068<sup>a</sup> | .150 | 2.283   | 0.741                  | 7.033                                |                |     |
|                           | 3-Mo Follow-up × Group     | 0.985| 0.586 | 2.828<sup>a</sup> | .093 | 2.677   | 0.850                  | 8.432                                |                |     |
|                           | Post-treatment × Group     | 1.579| 0.568 | 7.713<sup>a</sup> | .005 | 4.848   | 1.591                  | 14.772                               |                |     |
|                           | Baseline × Group           | 0    | –     | –               | –    | 1       | –                      | –                                    |                |     |
| Environmental reactivity | 30-Mo Follow-up × Group    | –0.338| 0.546 | 0.384<sup>a</sup> | .535 | 0.713   | 0.245                  | 2.079                                |                |     |
|                           | 12-Mo Follow-up × Group    | –0.758| 0.548 | 1.911<sup>a</sup> | .167 | 0.469   | 0.160                  | 1.373                                |                |     |
|                           | 6-Mo Follow-up × Group     | –0.379| 0.530 | 0.512<sup>a</sup> | .474 | 0.684   | 0.242                  | 1.933                                |                |     |
|                           | 3-Mo Follow-up × Group     | 0.085| 0.517 | 0.027<sup>a</sup> | .870 | 1.088   | 0.395                  | 2.995                                |                |     |
|                           | Post-treatment × Group     | 0.011| 0.590 | 0.000<sup>a</sup> | .985 | 1.011   | 0.318                  | 3.215                                |                |     |
|                           | Baseline × Group           | 0    | –     | –               | –    | 1       | –                      | –                                    |                |     |
| Guilt                    | 30-Mo Follow-up × Group    | –0.478| 0.566 | 0.714<sup>a</sup> | .398 | 0.620   | 0.205                  | 1.879                                |                |     |
|                           | 12-Mo Follow-up × Group    | 0.165| 0.686 | 0.058<sup>a</sup> | .810 | 1.179   | 0.308                  | 4.523                                |                |     |
|                           | 6-Mo Follow-up × Group     | 0.714| 0.565 | 1.597<sup>a</sup> | .206 | 2.043   | 0.675                  | 6.186                                |                |     |
|                           | 3-Mo Follow-up × Group     | 1.161| 0.563 | 4.262<sup>a</sup> | .039 | 3.195   | 1.060                  | 9.624                                |                |     |
|                           | Post-treatment × Group     | 1.031| 0.482 | 4.581<sup>a</sup> | .032 | 2.804   | 1.091                  | 7.206                                |                |     |
|                           | Baseline × Group           | 0    | –     | –               | –    | 1       | –                      | –                                    |                |     |
| Pessimism                | 30-Mo Follow-up × Group    | 1.123| 0.791 | 2.019<sup>a</sup> | .155 | 3.075   | 0.653                  | 14.483                               |                |     |
|                           | 12-Mo Follow-up × Group    | 0.592| 0.647 | 0.837<sup>a</sup> | .360 | 1.808   | 0.508                  | 6.430                                |                |     |
|                           | 6-Mo Follow-up × Group     | 1.296| 0.601 | 4.660<sup>a</sup> | .031 | 3.655   | 1.127                  | 11.859                               |                |     |
|                           | 3-Mo Follow-up × Group     | 1.501| 0.608 | 6.094<sup>a</sup> | .014 | 4.486   | 1.362                  | 14.769                               |                |     |
|                           | Post-treatment × Group     | 1.715| 0.543 | 9.961<sup>a</sup> | .002 | 5.555   | 1.915                  | 16.113                               |                |     |
|                           | Baseline × Group           | 0    | –     | –               | –    | 1       | –                      | –                                    |                |     |
| Work and interests       | 30-Mo Follow-up × Group    | 0.072| 0.730 | 0.010<sup>a</sup> | .921 | 1.075   | 0.257                  | 4.494                                |                |     |
|                           | 12-Mo Follow-up × Group    | 0.850| 0.702 | 1.468<sup>a</sup> | .226 | 2.340   | 0.592                  | 9.254                                |                |     |
|                           | 6-Mo Follow-up × Group     | 1.567| 0.743 | 4.453<sup>a</sup> | .035 | 4.791   | 1.118                  | 20.533                               |                |     |
|                           | 3-Mo Follow-up × Group     | 0.622| 0.675 | 0.850<sup>a</sup> | .357 | 1.863   | 0.496                  | 6.990                                |                |     |
|                           | Post-treatment × Group     | 1.349| 0.631 | 4.565<sup>a</sup> | .033 | 3.853   | 1.118                  | 13.278                               |                |     |
|                           | Baseline × Group           | 0    | –     | –               | –    | 1       | –                      | –                                    |                |     |
| CID Item            | Parameter                  | B       | SE     | Exp (B) | Wald 95% CI for Exp(B) | Test of Model Effect Time x Group |
|---------------------|----------------------------|---------|--------|---------|------------------------|----------------------------------|
|                     |                            |         | Wald Chi-square | P     | Lower | Upper | Wald Chi-square | P    |
| Energy and fatigue  | 30-Mo Follow-up × Group    | 0.229   | 0.515  | 0.198a  | .656 | 1.257 | 0.459 | 3.449 | 14.448b | .013 |
|                     | 12-Mo Follow-up × Group    | 0.402   | 0.459  | 0.768a  | .381 | 1.495 | 0.608 | 3.675 |         |     |
|                     | 6-Mo Follow-up × Group     | 0.809   | 0.510  | 2.510a  | .113 | 2.245 | 0.825 | 6.104 |         |     |
|                     | 3-Mo Follow-up × Group     | 0.990   | 0.475  | 4.339a  | .037 | 2.692 | 1.060 | 6.835 |         |     |
|                     | Post-treatment × Group     | 1.432   | 0.476  | 9.066a  | .003 | 4.187 | 1.649 | 10.636 |         |     |
|                     | Baseline × Group           | 0       | –      | –       | –   | 1     | –     | –     |         |     |
| Generalized anxiety | 30-Mo Follow-up × Group    | 0.084   | 0.565  | 0.022a  | .882 | 1.088 | 0.359 | 3.294 | 5.101b | .404 |
|                     | 12-Mo Follow-up × Group    | 0.173   | 0.603  | 0.082a  | .775 | 1.188 | 0.365 | 3.872 |         |     |
|                     | 6-Mo Follow-up × Group     | –0.196  | 0.591  | 0.110a  | .740 | 0.822 | 0.258 | 2.617 |         |     |
|                     | 3-Mo Follow-up × Group     | –0.296  | 0.644  | 0.211a  | .646 | 0.744 | 0.211 | 2.629 |         |     |
|                     | Post-treatment × Group     | 0.771   | 0.528  | 2.130a  | .144 | 2.161 | 0.768 | 6.084 |         |     |
|                     | Baseline × Group           | 0       | –      | –       | –   | 1     | –     | –     |         |     |
| Phobic anxiety      | 30-Mo Follow-up × Group    | –0.042  | 0.686  | 0.004a  | .952 | 0.959 | 0.250 | 3.678 | 0.295b | .998 |
|                     | 12-Mo Follow-up × Group    | –0.164  | 0.586  | 0.078a  | .780 | 0.849 | 0.269 | 2.676 |         |     |
|                     | 6-Mo Follow-up × Group     | 0.062   | 0.653  | 0.009a  | .925 | 1.064 | 0.296 | 3.827 |         |     |
|                     | 3-Mo Follow-up × Group     | –0.034  | 0.577  | 0.003a  | .953 | 0.967 | 0.312 | 2.998 |         |     |
|                     | Post-treatment × Group     | –0.139  | 0.461  | 0.091a  | .763 | 0.870 | 0.352 | 2.148 |         |     |
|                     | Baseline × Group           | 0       | –      | –       | –   | 1     | –     | –     |         |     |
| Phobic avoidance    | 30-Mo Follow-up × Group    | 0.522   | 0.797  | 0.429a  | .512 | 1.685 | 0.354 | 8.034 | 2.849b | .723 |
|                     | 12-Mo Follow-up × Group    | 0.311   | 0.684  | 0.206a  | .650 | 1.364 | 0.357 | 5.216 |         |     |
|                     | 6-Mo Follow-up × Group     | 1.413   | 1.134  | 1.554a  | .213 | 4.108 | 0.445 | 37.904 |         |     |
|                     | 3-Mo Follow-up × Group     | –0.322  | 0.723  | 0.198a  | .656 | 0.725 | 0.176 | 2.990 |         |     |
|                     | Post-treatment × Group     | 0.522   | 0.659  | 0.627a  | .428 | 1.686 | 0.463 | 6.137 |         |     |
|                     | Baseline × Group           | 0       | –      | –       | –   | 1     | –     | –     |         |     |
| Somatic anxiety     | 30-Mo Follow-up × Group    | –0.861  | 0.502  | 2.944a  | .086 | 0.423 | 0.158 | 1.130 | 11.610b | .041 |
|                     | 12-Mo Follow-up × Group    | –0.475  | 0.449  | 1.123a  | .289 | 0.622 | 0.258 | 1.498 |         |     |
|                     | 6-Mo Follow-up × Group     | –1.051  | 0.574  | 3.350a  | .067 | 0.350 | 0.113 | 1.077 |         |     |
|                     | 3-Mo Follow-up × Group     | 0.272   | 0.437  | 0.388a  | .533 | 1.312 | 0.558 | 3.089 |         |     |
|                     | Post-treatment × Group     | –0.322  | 0.415  | 0.600a  | .439 | 0.725 | 0.321 | 1.636 |         |     |
|                     | Baseline × Group           | 0       | –      | –       | –   | 1     | –     | –     |         |     |
| CID Item                  | Parameter          |  | Test of the Hypothesis | Wald 95% CI for Exp(\(B\)) | Test of Model Effect Time × Group |
|--------------------------|--------------------|-----------------------------|-----------------------------|---------------------------------|----------------------------------|
|                          |                    |  | Wald Chi-square | \(P\) | Lower | Upper | Wald Chi-square | \(P\) |
| Anorexia                 | 30-Mo Follow-up × Group | 0.812 | 1.352 | 0.360\(^a\) | .548 | 2.252 | 0.159 | 31.887 | 0.960\(^b\) | .811 |
|                         | 12-Mo Follow-up × Group | –0.760 | 1.374 | 0.306\(^a\) | .580 | 0.468 | 0.032 | 6.904 |                                   |        |
|                         | 6-Mo Follow-up × Group | –0.194 | 0.609 | 0.101\(^a\) | .750 | 0.824 | 0.250 | 2.719 |                                   |        |
|                         | 3-Mo Follow-up × Group | – | – | – | – | – | – | – |                                   |        |
|                         | Post-treatment × Group | – | – | – | – | – | 1 | – | – |        |
|                         | Baseline × Group    | 0 | – | – | – | – | – | – | – |        |
| Increased appetite       | 30-Mo Follow-up × Group | –1.426 | 0.935 | 2.325\(^a\) | .127 | 0.240 | 0.038 | 1.502 | 7.604\(^b\) | .179 |
|                         | 12-Mo Follow-up × Group | –0.060 | 1.131 | 0.003\(^a\) | .958 | 0.942 | 0.103 | 8.642 |                                   |        |
|                         | 6-Mo Follow-up × Group | –0.952 | 0.975 | 0.954\(^a\) | .329 | 0.386 | 0.057 | 2.609 |                                   |        |
|                         | 3-Mo Follow-up × Group | –0.311 | 0.939 | 0.110\(^a\) | .740 | 0.733 | 0.116 | 4.611 |                                   |        |
|                         | Post-treatment × Group | –2.267 | 1.034 | 4.809\(^a\) | .028 | 0.104 | 0.014 | 0.786 |                                   |        |
|                         | Baseline × Group    | 0 | – | – | – | – | 1 | – | – |        |
| Irritability             | 30-Mo Follow-up × Group | 0.066 | 0.671 | 0.010\(^a\) | .921 | 1.069 | 0.287 | 3.984 | 5.218\(^b\) | .390 |
|                         | 12-Mo Follow-up × Group | 0.157 | 0.638 | 0.061\(^a\) | .805 | 1.170 | 0.335 | 4.088 |                                   |        |
|                         | 6-Mo Follow-up × Group | 0.744 | 0.556 | 1.791\(^a\) | .181 | 2.103 | 0.708 | 6.249 |                                   |        |
|                         | 3-Mo Follow-up × Group | –0.494 | 0.598 | 0.684\(^a\) | .408 | 0.610 | 0.189 | 1.968 |                                   |        |
|                         | Post-treatment × Group | 0.231 | 0.557 | 0.172\(^a\) | .679 | 1.259 | 0.423 | 3.749 |                                   |        |
|                         | Baseline × Group    | 0 | – | – | – | – | 1 | – | – |        |
| Early insomnia           | 30-Mo Follow-up × Group | 2.571 | 1.140 | 5.084\(^a\) | .024 | 13.074 | 1.400 | 122.137 | 12.675\(^b\) | .027 |
|                         | 12-Mo Follow-up × Group | –0.055 | 0.875 | 0.004\(^a\) | .950 | 0.946 | 0.170 | 5.260 |                                   |        |
|                         | 6-Mo Follow-up × Group | 1.354 | 0.898 | 2.274\(^a\) | .132 | 3.873 | 0.666 | 22.509 |                                   |        |
|                         | 3-Mo Follow-up × Group | 1.678 | 0.874 | 3.690\(^a\) | .055 | 5.354 | 0.966 | 29.660 |                                   |        |
|                         | Post-treatment × Group | 2.578 | 0.885 | 8.498\(^a\) | .004 | 13.174 | 2.327 | 74.574 |                                   |        |
|                         | Baseline × Group    | 0 | – | – | – | – | 1 | – | – |        |
| Delayed insomnia         | 30-Mo Follow-up × Group | 0.488 | 0.877 | 0.309\(^a\) | .578 | 1.628 | 0.292 | 9.089 | 3.114\(^b\) | .682 |
|                         | 12-Mo Follow-up × Group | 0.340 | 0.905 | 0.141\(^a\) | .707 | 1.404 | 0.238 | 8.270 |                                   |        |
|                         | 6-Mo Follow-up × Group | –0.572 | 0.829 | 0.477\(^a\) | .490 | 0.564 | 0.111 | 2.863 |                                   |        |
|                         | 3-Mo Follow-up × Group | –0.065 | 0.748 | 0.007\(^a\) | .931 | 0.937 | 0.216 | 4.062 |                                   |        |
|                         | Post-treatment × Group | 0.236 | 0.837 | 0.080\(^a\) | .778 | 1.266 | 0.246 | 6.526 |                                   |        |
|                         | Baseline × Group    | 0 | – | – | – | – | 1 | – | – |        |

Abbreviations: CBT/WBT, sequential combination of cognitive-behavioral therapy and well-being therapy; CID, clinical interview for depression; CM, clinical management.

\(^a\)df = 1;
\(^b\)df = 5;
\(^c\)df = 3.
These findings provide further support to the incremental validity of the DCPR system in medical settings.22,31 Figure 1 illustrates the comprehensive assessment of mood disturbances that was performed in the present study on ACS patients. Our findings suggest a substantial overlap between depression and demoralization, as reported also in previous studies of medically ill patients,22,33 even though depressed patients do not necessarily meet the criteria for demoralization, and an important proportion of patients with demoralization do not meet diagnostic criteria for depression.22,33,35 Further, this study provides support to the distinctive clinical features of these two diagnostic entities. In line with prior research,32,35 we found that specific somatic symptoms (such as fatigue and changes of appetite) are more likely to characterize depressed patients (and may act as “cardio-toxic” factors), whereas abnormal reactivity to social environment is more frequently related to demoralization.

Associations of demoralization with dimensional psychological measures provide further support to the incremental validity and clinical utility of the DCPR system.22 Consistently with previous research,4,36,37 demoralization was found to be significantly associated with lower self-reported PWB and greater distress. PWB represents a neglected area in traditional psychiatric assessment, despite the growing literature supporting its buffering role in coping with stress and its favorable impact on disease course.30,38 PWB, indeed, was reported to be associated with reduced gene expression of conserved transcriptional response to adversity,49 which is usually elicited by persistent stress2 and involved in the pathophysiology of cardiovascular diseases.51

The DCPR interview allowed the detection of Type A behavior (TAB)13,42 in 28.1% of the sample, in line with other studies reporting the presence of TAB in about one third of patients with coronary heart disease.14 Moreover, similarly to previous studies,44 the present investigation showed that Type A often occurs without a DSM diagnosis and it is more frequently associated with demoralization than with depression.

The Clinical Interview for Depression23,24 yielded the most frequently reported depressive symptoms characterizing patients suffering from ACS. Among these symptoms, reactivity to social environment, low physical energy, depressed mood and somatic anxiety, were the most common. Reactivity to social environment refers to variations of mood and symptomatology (ie, either improvement or worsening), as a reaction to environmental circumstances. This characteristic has been found to sensitively discriminate between different subgroups of depressed patients.44-46 It is also very common in patients with neurocirculatory asthenia47 and cyclothymic disturbances.48 Glass and Contrada49 suggested that individuals who are prone to develop coronary diseases are more likely to display alternating coping patterns in challenging situations. Specifically, initial coping efforts could be manifested as behavioral hyper-reactivity (ie, Type A behavior and manic/hypomanic symptoms), which could be then followed by hypo-reactivity (including demoralization and depression) after repeated failure to assert control and/or attain relevant goals. These affective and behavioral transitions originally observed in individuals with Type A have been found to be similar to mood swings of bipolar patients,50 suggesting that in cardiac patients with Type A behavior, depressive symptoms following a cardiovascular event may be part of a subsyndromal bipolar disorder.11,20 This hypothesis seems to be supported by the findings of the present study, given the high rate of reactivity to social environment in ACS patients and the fact that almost half of patients with Type A behavior were also demoralized and/or depressed.

Somatic manifestations of psychological distress, such as somatic symptoms of depression (ie, low energy and fatigue) and physical manifestations of anxiety (ie, sweating, shaking, muscle tension, and difficult breathing), were found to be extremely common in our sample. These data are in line with literature showing that approximately two thirds of patients with depression in medical settings—especially older adults51—present with somatic symptoms,52 which could be interpreted as prodromal signs of mood disturbances and thus represent helpful indicators for the diagnostic process.53 Compared to depression characterized by cognitive symptoms, depression with prevalent somatic symptoms seems to be more “cardio-toxic”54 since it may have worse health outcomes, such as reduced heart rate variability,55 worse cardiovascular prognosis55 and higher risk of all-cause mortality.56 A meta-analysis57 showed that the severity of somatic symptoms of depression constituted a better predictor of mortality than affective and cognitive symptoms in patients with myocardial infarction. Recently, Job et al.58 prospectively examined a large cohort of adults aged over 50 years old and found that hair cortisol and plasma C-reactive protein exhibited stronger relationships with somatic rather than with cognitive/affective symptoms of depression, underlining the importance to consider symptom-specific effects in future studies on pathophysiological mechanisms.

On the same vein, somatic symptoms of anxiety have been identified as predictors of coronary heart disease2 and contributors to disability in late life, particularly in the presence of depression,60,61 suggesting that the identification and treatment of these symptoms may improve functional outcomes among older depressed adults. Given the significant overlap of physical symptoms of medical disorders with somatic and anxiety symptoms of depression, it is necessary to disentangle the associations of these symptom clusters with functional impairment.62-66 The use of the clinimetric approach for psychological assessment presented in the current study could be important to this purpose.

Furthermore, because of the clinimetric properties of the CID,24 particularly discriminant validity and sensitivity to changes with treatment, we were able to detect which depressive symptoms may benefit more from a sequential combination of cognitive-behavioral techniques and strategies geared to euthymia. Indeed, CBT/WBT was found to be associated with significantly greater relief of guilt and pessimism, as well as with an amelioration of somatic symptoms of anxiety and quality of sleep. In the present study, the addition of sessions dedicated to the pursuit of euthymia (ie, WBT), that were aimed at promoting integration of psychic forces, a unifying outlook on life, and resistance to stress,65-67 proved their additional value on relieving depressive symptoms and promoting a balanced functioning. Indeed, sequential combination of treatments in depression was found to entail a lower likelihood of relapse.68

Both CBT/WBT and CM were associated with significant improvements of depressed mood. This finding supports the hypothesis that the presence of demoralization might help identify those patients with a heightened susceptibility to nonspecific elements of treatment (such as offering a healing setting, encouragement, and instilling hopes of improvement), which provide reduction of isolation and pave the ground for therapeutic alliance, enhancing the process of change.69 CM, indeed, represents an active form of control that—unlike control conditions used in previous trials57—allows discrimination of specific and nonspecific ingredients of the psychotherapeutic approach.70,71

This investigation presents some limitations that should be mentioned, namely the lack of follow-up data on...
non-participants and the low rate of ACS patients who agreed to undergo the initial psychological assessment (38.9% of 740 ACS patients screened by the cardiologists), which—although it could mitigate the conclusion—is in line with participation rate reported elsewhere and reflects demographic characteristics of ACS patients in Italy (ie, prevalence of males and females). Despite these limitations, the present study has several strengths, such as the clinical homogeneity of the sample (ie, all participants had a first episode of ACS), the longitudinal and multicenter design, and the innovative, clinimetric approach to psychological assessment, which yielded new, important clinical insights into mood disturbances in ACS.

Conclusions

Expanding the assessment of mood disturbances from the identification of DSM depressive disorders to a broader number of related variables may yield important insights into the psychological state of patients with ACS. Assessing a wide spectrum of affective symptoms, detecting the presence of demoralization and type A behavior, and evaluating PWB and distress by dimensional self-rating tools, support the clinical relevance of subthreshold affective symptoms, detecting the presence of demoralization and related variables may yield important insights into the psychological aspects of ACS patients, which may allow subtyping of patients based on specific psychological profiles and provide therapeutic and prognostic indications.

Funding. This work was supported by a grant from the Compagnia di San Paolo di Torino (Italy) to C.R.

Disclosures. The authors declare that there is no conflict of interest.

Author Contributions. Conceptualization: S.G., G.A.F., C.R.; Data curation: S.G., C.R.; Formal analysis: S.G.; Funding acquisition: C.R.; Investigation: S.G., S.B., J.G., I.S., E.M.; Methodology: S.G., G.A.F., C.R.; Project administration: S.G., S.B., G.A.-D., C.R.; Resources: S.B., G.A.-D., C.R.; Supervision: R.R., G.A.-D., G.A.F., C.R.; Validation: G.A.F., C.R.; Visualization: S.G.; Writing—original draft: S.G., G.A.F., C.R.; Writing—review and editing: S.G., S.B., J.G., I.S., E.M., R.R., G.A.-D., G.A.F., C.R.

References

1. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129(12):1350–1369.
2. Carney RM, Freedland KE. Depression and coronary heart disease. Nat Rev Cardiol. 2017;14(3):145–155.
3. Vaccarino V, Badimon L, Bremner JD, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687–1696.
4. Rafanelli C, Roncuzzi R, Milaneschi Y, et al. Stressful life events, depression and demoralization as risk factors for acute coronary heart disease. Psychol Health. 2005;20(4):179–184.
5. Kuhlmann SL, Arolt V, Haverkamp W, et al. Prevalence, 12-month prognosis, and clinical management need of depression in coronary heart disease patients. Psychother Psychosom. 2019;88(5):300–311.
6. de Figueiredo JM, Frank JD. Subjective incompetence, the clinical hallmark of demoralization. Compr Psychiatry. 1982;23(4):353–363.
7. Rafanelli C, Roncuzzi R, Finos I, et al. Psychological assessment in cardiac rehabilitation. Psychother Psychosom. 2003;72(6):343–349.
8. Rafanelli C, Milaneschi Y, Roncuzzi R. Minor depression as a short-term risk factor in outpatients with congestive heart failure. Psychosomatics. 2009;50(5):493–499.
9. Rafanelli C, Milaneschi Y, Roncuzzi R, Pancaldi LG. Dysthymia before myocardial infarction as a cardiac risk factor at 2.5 year follow-up. Psychosomatics. 2010;51(8):9–13.
10. Rafanelli C, Offidani E, Gostoli S, Roncuzzi R. Psychological correlates in patients with different levels of hypertension. Psychiatry Res. 2012;198(1):154–160.
11. Rafanelli C, Sirri L, Grandi S, Fava GA. Is depression the wrong treatment target for improving outcome in coronary artery disease? Psychother Psychosom. 2013;82(5):285–291.
12. Fava GA, Rafanelli C, Tomba E. The clinical process in psychiatry: a clinimetric approach. J Clin Psychiatry. 2012;73(2):177–184.
13. Rafanelli C, Gostoli S, Buzzichelli S, et al. Sequential combination of cognitive-behavioral therapy and well-being therapy in depressed patients with acute coronary syndromes. A randomized controlled trial (TREATED-ACS Study). Psychother Psychosom. 2020;89(6):345–356.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. rev. Washington, DC: American Psychiatric Association; 2000.
15. Fava GA, Freyberger HJ, Rech P, et al. Diagnostic criteria for use in psychosomatic research. Psychother Psychosom. 1995;63(1):1–8.
16. Fava GA. Well-Being Therapy: Treatment Manual and Clinical Applications. Basel: Karger Medical & Scientific Publishers; 2016.
17. Fava GA, Sonino N. Depression associated with medical illness. CNS Drugs. 1996;5(3):175–189.
18. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version. New York: Biometrics Research, New York State Psychiatric Institute; 2002.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Press; 2013.
20. Porcelli P, Sonino N. Psychological Factors Affecting Medical Conditions: A New Classification for DSM-V. Advances in Psychosomatic Medicine. Basel: Karger; 2007.
21. Galeazzi GM, Ferrari S, Mackinnon A, Rigatelli M. Interrater reliability, prevalence, and relation to ICD-10 diagnoses of the Diagnostic Criteria for Psychosomatic Research in consultation-liaison psychiatry patients. Psychosomatics. 2004;45(5):386–393.
22. Guidi J, Piolanti A, Berrocal C, Gostoli S, Carrozino D. Incremental validity of the Diagnostic Criteria for Psychosomatic Research – Revised (DCPR-R) to clinical assessment in primary care. Psychiatry Res. 2020;291:1–11233.
23. Paykel ES. The clinical interview for depression. Development, reliability and validity. J Affect Disord. 1985;9(1):85–96.
24. Guidi J, Fava GA, Bech P, Paykel E. The Clinical Interview for Depression: a comprehensive review of studies and clinimetric properties. Psychother Psychosom. 2011;80(1):10–27.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):275–296.
26. Carrozino D, Patterno C, Fava GA, Guidi J. The Hamilton Rating Scales for Depression: a critical review of clinimetric properties of different versions. Psychother Psychosom. 2020;89(3):133–150.
27. Kellner R. A symptom questionnaire. J Clin Psychiatry. 1987;48(7):268–274.
28. Benasi G, Fava GA, Rafanelli C. Kellner’s Symptom Questionnaire, a highly sensitive patient-reported outcome measure: systematic review of clinimetric properties. Psychother Psychosom. 2020;89(2):74–89.
29. Ryff CD. Happiness is everything, or is it? Explorations on the meaning of psychological well-being. J Pers Soc Psychol. 1989;57(6):1069–1081.
30. Ryff CD. Psychological well-being revisited: advances in the science and practice of eudaimonia. Psychother Psychosom. 2014;83(1):10–28.
31. Gostoli S, Montecchiari M, Ursge A, et al. The clinical utility of a comprehensive psychosomatic assessment in the program for colorectal cancer prevention: a cross-sectional study. Sci Rep. 2021;11:15575
32. Guidi J, Fava GA, Picardi A, et al. Subtyping depression in the medically ill by cluster analysis. J Affect Disord. 2011;132(3):383–388.
33. Rafanelli C, Guidi J, Gostoli S, Tomba E, Porcelli P, Grandi S. Subtyping demoralization in the medically ill by cluster analysis. Eur J Psychiatry. 2013;27(1):7–17.
34. Rafanelli C, Gostoli S, Roncuzzi R, Sassone B. Psychological correlates of vasovagal versus medically unexplained syncope. Gen Hosp Psychiatry. 2013;35(3):246–252.
35. de Figueiredo JM. Depression and demoralization: phenomenologic differences and research perspectives. Compr Psychiatry. 1993;34(5):308–311.
36. Tecuta L, Tomba E, Grandi S, Fava GA. Demoralization: a systematic review on its clinical characterization. Psychol Med. 2015;45(4):673–691.
37. Tecuta L, Fava GA, Tomba E. An innovative approach for the assessment of mood disturbances in patients with eating disorders. CNS Spectr. 2020;25(1):71–78.
38. Pressman SD, Cohen S. Does positive affect influence health? Psychol Bull. 2005;131(6):925–971.
39. Frederickson BL, Grewen KM, Algoes SB, et al. Psychological correlates of psychological well-being and the human conserved transcriptional response to adversity. PLoS One. 2015;10(3):e0212839.
40. Cole SW. Human social genomics. PLoS Genet. 2014;10(8):e1004601.
41. Nemeroff CB, Goldschmidt-Clermont PJ. Heartache and heartbreak – the link between depression and cardiovascular disease. Nat Rev Cardiol. 2012;9(10):526–539.
42. Friedman M, Rosenman RH. Type A Behavior and Your Heart. New York: Knopf; 1974.
43. Sirli L, Fava GA, Guidi J, et al. Type A behavior: a reappraisal of its characteristics in cardiovascular disease. Int J Clin Pract. 2012;66(9):854–861.
44. Paykel ES. Classification of depressed patients - a cluster analysis derived grouping. Br J Psychiatry. 1971;118(544):275–288.
45. Paykel ES, Klerman GL, Prusoff BA. Treatment setting and clinical depression. Arch Gen Psychiatry. 1970;22(1):11–21.
46. Paykel ES, Klerman GL, Prusoff BA. Depressive prognosis and endogenous-neurotic distinction. Psychol Med. 1974;4(1):57–64.
47. Fava GA, Magelli C, Savron G, et al. Neurocirculatory asthenia - a reassessment using modern psychosomatic criteria. Acta Psychiatr Scand. 1994;89(5):314–319.
48. Tomba E, Rafanelli C, Grandi S, Guidi J, Fava GA. Clinical configuration of cyclothymic disturbances. J Affect Disord. 2012;139(3):244–249.
49. Glass DC, Contrada RJ. Bipolar disorder, Type A behaviour and coronary disease. Health Psychol Rev. 2012;6(2):180–196.
50. Dargél AA, Volant S, Saha S, et al. Activation levels, cardiovascular risk, and functional impairment in remitted bipolar patients: clinical relevance of a dimensional approach. Psychother Psychosom. 2019;88(1):45–47.
51. Hegeman J, Kok R, Van der Mast R, Giltay E. Phenomenology of depression in older compared with younger adults: meta-analysis. Br J Psychiatry. 2012;200(4):275–281.
52. Tylee A, Gandhi P. The importance of somatic symptoms in depression in primary care. Prim Care Companion J Clin Psychiatry. 2005;7(4):167–176.
53. Benasi G, Fava GA, Guidi J. Prodomal symptoms in depression: a systematic review. Psychother Psychosom. 2021;90:365–372.
54. de Jonge P, Mangano D, Whooley MA. Differential association of cognitive and somatic depressive symptoms with heart rate variability in patients with stable coronary heart disease: findings from the Heart and Soul Study. Psychosom Med. 2007;69(8):735–739.
55. O’Neill A, Sanderson K, Oldenburg B. Depression as a predictor of work resumption following myocardial infarction (MI): a review of the evidence. BMC Qual Life Outcomes. 2010;8:95.
56. Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call for recognition. Circulation. 2005;111(3):250–253.
57. de Miranda Azevedo R, Roest AM, Hoen PW, De Jonge P. Cognitive/affective and somatic/affective symptoms of depression in patients with heart disease and their association with cardiovascular prognosis: a meta-analysis. Psychol Med. 2014;44(13):2689–2703.
58. Iob E, Kirschbaum C, Steptoe A. Persistent depressive symptoms, HPA-axis hyperactivity, and inflammation: the role of cognitive-affective and somatic symptoms. Mol Psychiatry. 2020;25(5):1130–1140.
59. Nabi H, Hall M, Koskenvuo M, et al. Psychological and somatic symptoms of anxiety and risk of coronary heart disease: the health and social support prospective cohort study. Biol Psychiatry. 2010;67(4):378–385.
60. Lenze EJ, Rogers JC, Martire LM, et al. The association of late-life depression and anxiety with physical disability: a review of the literature and prospectus for future research. Am J Geriatr Psychiatry. 2001;9(2):113–135.
61. Morin RT, Nelson C, Bickford D, Insel PS, Mackin RS. Somatic and anxiety symptoms of depression are associated with disability in late life depression. Aging Ment Health. 2020;24(8):1225–1228.
62. Galatzer-Levy IR, Bonanno GA. Optimism and death: predicting the course and consequences of depression trajectories in response to heart attack. Psychol Sci. 2014;25(12):2177–2188.
63. Sin NL, Yaffe K, Whooley MA. Depressive symptoms, cardiovascular disease severity, and functional status in older adults with coronary heart disease: the heart and soul study. J Am Geriatr Soc. 2015;63(1):8–15.
64. Morin RT, Galatzer-Levy IR, Maccallum F, Bonanno GA. Do multiple health events reduce resilience when compared with single events? Health Psychol. 2017;36(8):721–728.
65. Fava GA, Bech P. The concept of euthymia. Psychother Psychosom. 2016;85(1):1–5.
66. Fava GA, Guidi J. The pursuit of euthymia. World Psychiatry. 2020;19(1):40–50.
67. Guidi J, Fava GA. The emerging role of euthymia in psychotherapy research and practice. Clin Psychol Rev. 2020;82:101941.
68. Guidi J, Fava GA. Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(3):261–269.
69. Tomba E, Tecuta L, Guidi J, Grandi S, Rafanelli C. Demoralization and response to psychotherapy: a pilot study comparing the sequential combination of cognitive-behavioral therapy and well-being therapy with clinical management in cyclothymic disorder. Psychother Psychosom. 2016;85(5):56–57.
70. Reavell J, Hopkinson M, Clarksmith D, Lane DA. Effectiveness of cognitive-behavioral therapy for depression and anxiety in patients with cardiovascular disease: a systematic review and meta-analysis. Psychosom Med. 2018;80(3):742–753.
71. Fava GA, Guidi J, Rafanelli C, Ricksel K. The clinical inadequacy of the placebo model and the development of an alternative conceptual framework. Psychother Psychosom. 2017;86(6):332–340.
72. Guidi J, Brakemeier EL, Bockting CL, et al. Methodological recommendations for trials of psychological interventions. Psychother Psychosom. 2018;87(5):276–284.
73. Hansen RH, Hanash JA, Rasmussen A, Hansen JF, Bircket-Smith M. Comparison of participants and non-participants in a randomized study of prevention of depression in patients with acute coronary syndrome. Nord J Psychiatry. 2011;65(1):22–25.
74. De Luca L, Marini M, Gonzalez L, et al. Contemporary trends and age-specific sex differences in management and outcome for patients with ST-segment elevation myocardial infarction. J Am Heart Assoc. 2016;5(12):e004202.